The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.

ABSTRACT: The chemotherapeutic agent CX-5461, or pidnarulex, has been fast-tracked by the United States Food and Drug Administration for early-stage clinical studies of BRCA1-, BRCA2- and PALB2-mutated cancers. It is under investigation in phase I and II trials. Here, we find that, although CX-5461 exhibits synthetic lethality in BRCA1-/BRCA2-deficient cells, it also causes extensive, nonselective, collateral mutagenesis in all three cell lines tested, to magnitudes that exceed known environmental carcinogens.

SUBMITTER: Koh GCC 

PROVIDER: S-EPMC10786719 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature